Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024

Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024

€40,00
/
Tax included. Shipping calculated at checkout.
  • Free Shipping on orders over 45$
  • In stock, ready to ship
  • Inventory on the way

Cleveland Clinic Management of Checkpoint Inhibitor-Related Toxicity 2024

 Include: 35 videos + 1 pdf, size: 8.1 GB
Target Audience: immunologists
 Information:


Twelve checkpoint inhibitor therapies have been approved since 2011 in a wide variety of cancers, including tumor-agnostic indications for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer.

Immune checkpoint blockade leads to a new spectrum of dysimmune toxicity requiring collaboration between oncologist providers and specialists to improve the understanding of the mechanism, diagnosis, and management of irAEs. Six CAR T-cell therapies have been approved since 2017 for the treatment of blood cancers, including lymphomas, some forms of leukemia, and, most recently, multiple myeloma.

Medical subspecialists, nurses, nurse practitioners, physician assistants, pharmacists, and residents/ fellows are invited to attend.

Learning Objectives

As a result of attending the course, the participant will be able to:
  • Describe the mechanism of action associated with checkpoint inhibitor therapies and the biologics used in the treatment of immune-related adverse events.
  • Identify the spectrum of immune-related adverse events that can occur with immune checkpoint inhibitor therapies and CAR T-cell therapies.
  • Implement assessment criteria, diagnostic testing, and interventions to improve early identification and management of immune-related AEs.
  • Recognize the importance and necessity of the multidisciplinary approach in treatment of immune-related adverse events.

The Cleveland Clinic Management of Checkpoint Inhibitorrelated Toxicity 2024 is designed for a multidisciplinary audience. This includes medical subspecialists, nurses, nurse practitioners, physician assistants, pharmacists, and residents/fellows. The course aims to improve understanding of the mechanism, diagnosis, and management of immune-related adverse events (irAEs) associated with checkpoint inhibitor therapies and CAR T-cell therapies


 

 Topics:
  • brochure.pdf
  • Session 1 Future of irAE Management Abstract 1.mp4
  • Session 1 Future of irAE Management Abstract 2.mp4
  • Session 1 Future of irAE Management Challenges of irAE Management in Community Oncology Settings.mp4
  • Session 1 Future of irAE Management How are Inpatient irAEs Managed at Mass General.mp4
  • Session 1 Future of irAE Management How are irAEs Managed at Cleveland Clinic.mp4
  • Session 1 Future of irAE Management How are Outpatient irAEs Managed at Mass General.mp4
  • Session 1 Future of irAE Management Introduction Where are we now with irAE Management.mp4
  • Session 1 Future of irAE Management Panel Discussion Q&A.mp4
  • Session 1 Future of irAE Management Pharmacology of Steroids.mp4
  • Session 1 Future of irAE Management Q&A 1.mp4
  • Session 1 Future of irAE Management Q&A 2.mp4
  • Session 1 Future of irAE Management Refractory Therapies.mp4
  • Session 1 Future of irAE Management Wrap Up Adjourn Reception & Posters.mp4
  • SESSION 1 MANAGEMENT OF COMMON Dermatologic irAEs.mp4
  • SESSION 1 MANAGEMENT OF COMMON Endocrine irAEs.mp4
  • SESSION 1 MANAGEMENT OF COMMON irAEs Case Presentations Panel Discussion Q&A.mp4
  • SESSION 1 MANAGEMENT OF COMMON Pulmonary irAEs.mp4
  • SESSION 1 MANAGEMENT OF COMMON Rheumatologic irAEs.mp4
  • SESSION 2 KEYNOTE ADDRESS.mp4
  • SESSION 3 GUTSY FEELINGS Case Presentations Panel Discussion Q&A.mp4
  • SESSION 3 GUTSY FEELINGS Gastrointestinal irAEs.mp4
  • SESSION 3 GUTSY FEELINGS Hepatologic irAEs.mp4
  • SESSION 3 GUTSY FEELINGS Introduction.mp4
  • SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Infectious Disease.mp4
  • SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Introduction.mp4
  • SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED irAEs Case Presentations Panel Discussion Q&A.mp4
  • SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Nephrologic irAEs.mp4
  • SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Neurologic.mp4
  • SESSION 4 SPEED ROUNDS RECOGNITION OF UNDERAPPRECIATED Ophthalmologic irAEs.mp4
  • SESSION 5 HEME CAR T-cell and TIL Therapies.mp4
  • SESSION 5 HEME Case Presentations Panel Discussion Q&A.mp4
  • SESSION 5 HEME Hematologic irAEs.mp4
  • SESSION 5 HEME Introduction.mp4
  • SESSION 5 HEME Wrap Up Adjourn.mp4
  • Welcome Introduction.mp4

- Orders under 45$ will have a shipping charge of a flat rate of 15$.

-Orders over 45$ will have Free Shipping.

This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.

Testimonials

★★★★★


“I find the taste of Moringa tea to be very refreshing and it definitely gives me a feeling of ‘wellness’. I appreciate the ethics of the company. Am looking forward to trying the cream”

Elain
★★★★★


”I love knowing that everything is 100% chemical-free and tested in Canada. I also respect the sustainable farming approach that supports both Canada and Ethiopia.”

Alycia
★★★★★

Since I drink Moringa Tea I feel so much better. My mouth was always so dry but since I drink this tea I have so much saliva I drool.

I cannot believe how much it has helped me with my breathing. I love it. I even eat all the leaves - Thank you for introducing me to this herbal tea. I'm 85 years old.

Richard Dorge
Winnipeg, MB

Recently viewed